Saini Manu, Bajaj Mandeep Singh, Pushker Neelam, Meel Rachna, Saini Kulbhushan, Chaurasia Shweta, Mehta Aditi
Advanced Eye Centre, Post Graduate Institute of Medical Education and Research, Chandigarh, India.
Dr. Rajendra Prasad Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi, India.
Oman J Ophthalmol. 2022 Mar 2;15(1):56-60. doi: 10.4103/ojo.ojo_33_21. eCollection 2022 Jan-Apr.
The purpose of the study is to evaluate the safety and efficacy of adjunctive use of mitomycin-C (MMC) using two different concentrations 0.2 mg/ml and 0.4 mg/ml for lacrimal duct probing to treat the nasolacrimal duct obstruction (NLDO) in adults.
Prospective, an interventional comparative randomized pilot study of lacrimal duct probing conducted in the two study groups 0.02% MMC group ( = 30) and 0.04% MMC group ( = 30) in confirmed primary acquired NLDO of <1-year duration. Patency of lacrimal duct probing confirmed by syringing was compared at 1, 3, and 6-month follow-up in the two study groups, and corresponding subjective improvement of watering was appraised according to Kraft and Crawford grading.
Patency of lacrimal duct probing in 0.02% MMC versus 0.04% MMC group was 66.66%/73.33% ( = 0.71) at 1 month, 46.66%/66.66% ( = 0.09) at 3 months and 46.66%/66.66% ( = 0.03) at 6-month follow-up, respectively. Subjective improvement of watering (no watering and mild watering) observed in 0.02% MMC versus 0.04% MMC group was 46.66%/73.33% ( = 0.03), at 1 month, 66.66%/83.33% ( = 0.13) at 3 months and 56.66%/73.33% ( = 0.17) at 6-month follow-up.
Adult lacrimal duct probing with 0.04% MMC was associated with significant higher objective success rate than adult lacrimal duct probing with 0.02% MMC, without added concurrently side effects.
本研究旨在评估在成人泪道探通术中辅助使用两种不同浓度（0.2毫克/毫升和0.4毫克/毫升）的丝裂霉素C（MMC）治疗鼻泪管阻塞（NLDO）的安全性和有效性。
对确诊为病程小于1年的原发性后天性鼻泪管阻塞患者进行前瞻性、介入性比较随机试点研究，分为两个研究组，即0.02%MMC组（n = 30）和0.04%MMC组（n = 30）。在两个研究组中，于1、3和6个月随访时比较通过冲洗确认的泪道探通通畅情况，并根据克拉夫特和克劳福德分级评估相应的主观流泪改善情况。
在1个月时，0.02%MMC组与0.04%MMC组泪道探通通畅率分别为66.66%/73.33%（P = 0.71）；在3个月时，分别为46.66%/66.66%（P = 0.09）；在6个月随访时，分别为46.66%/66.66%（P = 0.03）。在1个月时，0.02%MMC组与0.04%MMC组观察到的主观流泪改善情况（无流泪和轻度流泪）分别为46.66%/73.33%（P = 0.03）；在3个月时，分别为66.66%/83.33%（P = 0.13）；在6个月随访时，分别为56.66%/73.33%（P = 0.17）。
与使用0.02%MMC进行成人泪道探通相比，使用0.04%MMC进行成人泪道探通的客观成功率显著更高，且无额外的并发副作用。
